The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma
Aging · 2024
DOI: 10.18632/aging.205782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Xudong Mao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China. Hauptthemen laut MEDLINE: Adenosine, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Zitieren
APA
Mao, X., Chen, X., Xu, Z., Ding, L., Luo, W., Lin, Y., Wang, R., Xia, L., Wang, M., & Li, G. (2024). The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma. Aging. https://doi.org/10.18632/aging.205782
Vancouver
Mao X, Chen X, Xu Z, Ding L, Luo W, Lin Y, et al. The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma. Aging. 2024. doi:10.18632/aging.205782
BibTeX
@article{Mao2024,
author = {Mao, Xudong and Chen, Xianjiong and Xu, Zhehao and Ding, Lifeng and Luo, Wenqin and Lin, Yudong and Wang, Ruyue and Xia, Liqun and Wang, Mingchao and Li, Gonghui},
title = {The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205782}
}
EUVIMED